Literature DB >> 15755310

Enhanced transcription of contractile 5-hydroxytryptamine 2A receptors via extracellular signal-regulated kinase 1/2 after organ culture of rat mesenteric artery.

Yong-Xiao Cao1, Lang-Chong He, Cang-Bao Xu, Guo-Gang Luo, Lars Edvinsson.   

Abstract

5-Hydroxytryptamine (5-HT) has been found to elicit enhanced contractile effects in some vascular disorders. The present study was designed to examine if vascular 5-HT2A receptors are up-regulated during organ culture and if the extracellular signal-regulated protein kinase 1/2 (ERK1/2) pathways are involved. Compared with fresh rat mesenteric artery ring segments, the contractile responses to 5-HT were significantly increased in the segments cultured for 6, 24 or 48 hr (P<0.05, P<0.01, P<0.01, respectively). The 5-HT-induced contraction occurred via 5-HT2A receptors, since the selective 5-HT2A antagonist ketanserin blocked the 5-HT-induced contraction in the fresh segments with a pA2 value 9.5 (slope was 0.98 with 95% confidence intervals from 0.8 to 1.1). A similar result was obtained in the segments cultured for 24 hr with a pA2 value of 9.43 (slope=0.91 and 95% confidence intervals between 0.45 to 2.3). In addition, the enhanced 5-HT2A receptor contraction occurred with a significant increase of 5-HT2A receptor mRNA (P<0.05). Organ culture of the mesenteric artery was found to activate ERK1/2 already within 1 and 3 hr. It is likely that the ERK1/2 pathways were involved as a initial switch, since the selective ERK1/2 pathway inhibitor SB386023 abolished both up-regulation of 5-HT2A mRNA transcription and the enhanced contractile response to 5-HT. These data reveal a role of ERK1/2 in up-regulation of 5-HT2A receptors and suggest a possibility to inhibit the enhanced responses to 5-HT by inhibition of the ERK1/2 pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755310     DOI: 10.1111/j.1742-7843.2005.pto960402.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  7 in total

1.  Disruption of actin cytoskeleton mediates loss of tensile stress induced early phenotypic modulation of vascular smooth muscle cells in organ culture.

Authors:  Jian-Pu Zheng; Donghong Ju; Jianbin Shen; Maozhou Yang; Li Li
Journal:  Exp Mol Pathol       Date:  2009-10-27       Impact factor: 3.362

2.  The enhanced endothelin-1-induced contraction in cultured coronary arteries from mature female pigs is not antagonized by 17beta-estradiol.

Authors:  Saigiridhar Tummala; Brent J F Hill
Journal:  Vascul Pharmacol       Date:  2006-12-09       Impact factor: 5.773

3.  Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery.

Authors:  Shun Watanabe; Takayuki Matsumoto; Mirai Oda; Kosuke Yamada; Junya Takagi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2015-11-17       Impact factor: 3.657

4.  IL-1beta induces murine airway 5-HT2A receptor hyperresponsiveness via a non-transcriptional MAPK-dependent mechanism.

Authors:  Yaping Zhang; Lars-Olaf Cardell; Mikael Adner
Journal:  Respir Res       Date:  2007-04-02

5.  Minimally modified LDL upregulates endothelin type A receptors in rat coronary arterial smooth muscle cells.

Authors:  Jie Li; Lei Cao; Cang-Bao Xu; Jun-Jie Wang; Yong-Xiao Cao
Journal:  Mediators Inflamm       Date:  2013-06-19       Impact factor: 4.711

6.  Mechanisms underlying a decrease in KCl-induced contraction after long-term serum-free organ culture of rat isolated mesenteric artery.

Authors:  Tomoka Morita; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  J Vet Med Sci       Date:  2014-04-01       Impact factor: 1.267

7.  Upregulation of 5-hydroxytryptamine receptor signaling in coronary arteries after organ culture.

Authors:  Chun-Yu Deng; Hui Yang; Su-Juan Kuang; Fang Rao; Yu-Mei Xue; Zhi-Ling Zhou; Xiao-Ying Liu; Zhi-Xin Shan; Xiao-Hong Li; Qiu-Xiong Lin; Shu-Lin Wu; Xi-Yong Yu
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.